New Delhi: Bharat Biotech’s Covaxin has proved a 77.8 efficacy rate fighting against Coronavirus, revealed by a medical journal Lancet. The made in India vaccine has demonstrated effectiveness against all variants of the SARS-CoV-2 virus.

The efficacy rate was confirmed through the evaluation of 130 confirmed cases, with 24 observed in the vaccine group against 106 in the placebo group, stated in the report.

According to phase 3 data, Covaxin was found 65.2 percent effective against delta variant and 93.4 percent effective against severe symptomatic Covid and 63/6 percent effective against asymptomatic Covid.

Bharat Biotech CMD Dr. Krishna Ella said that “ the peer-review of Covaxin phase 3 clinical trial data in the Lancet, an authoritative journal in global medicine, validates our commitment to data transparency and meeting the stringent peer-review standards of world-leading medical journals. This accomplishment reflects the undeterred commitment by my team members at Bharat Biotech, our public partners, the Indian Council of Medical Research, the National Institute of Virology, and the trust imposed by our trial participants who made this happen., he added.

Like the phase, 3 trial efficacy and safety study involved 25,800 volunteers across 25 sites in India and is the country's largest-ever clinical trial conducted for a Covid-19 vaccine.